Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

Farhad Ravandi; Stefan Faderl

doi:10.1016/j.leukres.2005.05.008

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

Leuk Res. 2006 Jan;30(1):103-5. doi: 10.1016/j.leukres.2005.05.008. Epub 2005 Jun 24.

Authors

Farhad Ravandi¹, Stefan Faderl

Affiliation

¹ Department of Leukemia, Box 428, University of Texas-M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. fravandi@mdanderson.org

PMID: 15979704
DOI: 10.1016/j.leukres.2005.05.008

Abstract

Treatment of adult T-cell leukemia (ATL) remains difficult. Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role in this setting. However, the associated immunosuppression is a concern in patients with viral-mediated disease.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Alemtuzumab
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / administration & dosage
Antineoplastic Agents / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Enzyme Inhibitors / administration & dosage
Female
Humans
Leukemia-Lymphoma, Adult T-Cell / drug therapy*
Leukemia-Lymphoma, Adult T-Cell / pathology
Middle Aged
Pentostatin / administration & dosage

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Agents
Enzyme Inhibitors
Pentostatin
Alemtuzumab